Splenic Volume As a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jul 2

PMID 34208673

Citations 8

Authors

Loick Galland

Julie Lecuelle

Laure Favier

Clea Fraisse

Aurelie Lagrange

Coureche Kaderbhai

Caroline Truntzer

Francois Ghiringhelli

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies targeting PD1/PD-L1 are game changers in advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported the prognostic role of splenic volume in digestive cancer and its correlation with the presence of immunosuppressive cells. The aim of this study was to evaluate the prognostic role of splenic volume in NSCLC patients treated with immune checkpoint inhibitors (ICIs). We conducted a retrospective study of 276 patients receiving ICIs for advanced NSCLC in the Georges François Leclerc Cancer Center. The association between splenic volume at baseline and at two months of therapy and progression-free survival (PFS) during ICI treatment or overall survival (OS) from ICI initiation was evaluated using univariate and multivariable Cox analyses. Splenic volume during treatment and the change in splenic volume were associated with poor PFS (respectively = 0.02 and = 0.001) and with OS (respectively < 1.10 and < 1.10). Baseline splenic volume at the first evaluation was also associated with poor OS ( = 0.001). LDH rate and dNLR were positively correlated with splenic volume, as well as with its evolution. After the adjustment of clinical variables, splenic volumes remained a predictive marker of immunotherapy efficacy. Splenic volume is a prognostic biomarker in patients with advanced NSCLC treated with ICIs.

Citing Articles

Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Zhu Y, She J, Sun R, Yan X, Huang X, Wang P Front Immunol. 2024; 15:1493773.

PMID: 39575263 PMC: 11578953. DOI: 10.3389/fimmu.2024.1493773.

Antitumoral effect of local injection of TLR-9 agonist emulsified in Lipiodol with systemic anti-PD-1 in a murine model of colorectal carcinoma.

Grindel A, Fretellier N, Soares M, Bouzakher N, Millot Maysounabe V, Santus R Front Immunol. 2024; 14:1272246.

PMID: 38292484 PMC: 10825566. DOI: 10.3389/fimmu.2023.1272246.

Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy.

Mo Z, Lv L, Mai Q, Li Q, He J, Zhang T J Immunother Cancer. 2024; 12(1).

PMID: 38290767 PMC: 10828840. DOI: 10.1136/jitc-2023-008191.

Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer.

Liu M, Yan G, Li Y, You R, Liu L, Zhang D Cancer Imaging. 2023; 23(1):116.

PMID: 38041154 PMC: 10691021. DOI: 10.1186/s40644-023-00640-0.

The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma.

Aslan V, Karabork Kilic A, Ozet A, Uner A, Gunel N, Yazici O BMC Cancer. 2023; 23(1):1045.

PMID: 37904131 PMC: 10617093. DOI: 10.1186/s12885-023-11558-y.

References

Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J . Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One. 2013; 8(2):e57114. PMC: 3577767. DOI: 10.1371/journal.pone.0057114. View

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D . Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018; 4(3):351-357. PMC: 5885829. DOI: 10.1001/jamaoncol.2017.4771. View

Chen Y, Yan H, Wang Y, Shi Y, Dai G . Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2017; 7(1):753. PMC: 5429710. DOI: 10.1038/s41598-017-00859-5. View

Trovato R, Fiore A, Sartori S, Cane S, Giugno R, Cascione L . Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3. J Immunother Cancer. 2019; 7(1):255. PMC: 6751612. DOI: 10.1186/s40425-019-0734-6. View

Liu C, Liu R, Wang B, Lian J, Yao Y, Sun H . Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. J Immunother Cancer. 2021; 9(1). PMC: 7813395. DOI: 10.1136/jitc-2020-001895. View

Garon E, Rizvi N, Hui R, Leighl N, Balmanoukian A, Eder J . Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21):2018-28. DOI: 10.1056/NEJMoa1501824. View

Gabrilovich D . Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017; 5(1):3-8. PMC: 5426480. DOI: 10.1158/2326-6066.CIR-16-0297. View

Ferrucci P, Ascierto P, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini G . Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol. 2016; 27(4):732-8. DOI: 10.1093/annonc/mdw016. View

Limagne E, Euvrard R, Thibaudin M, Rebe C, Derangere V, Chevriaux A . Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen. Cancer Res. 2016; 76(18):5241-52. DOI: 10.1158/0008-5472.CAN-15-3164. View

10.

Bronte V, Pittet M . The spleen in local and systemic regulation of immunity. Immunity. 2013; 39(5):806-18. PMC: 3912742. DOI: 10.1016/j.immuni.2013.10.010. View

11.

Toor S, Syed Khaja A, El Salhat H, Faour I, Kanbar J, Quadri A . Myeloid cells in circulation and tumor microenvironment of breast cancer patients. Cancer Immunol Immunother. 2017; 66(6):753-764. PMC: 5445142. DOI: 10.1007/s00262-017-1977-z. View

12.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A . Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget. 2018; 9(39):25617-25629. PMC: 5986639. DOI: 10.18632/oncotarget.25424. View

13.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

14.

Ghonim M, Ibba S, Tarhuni A, Errami Y, Luu H, Dean M . Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. 2021; 9(1). PMC: 7839867. DOI: 10.1136/jitc-2020-001643. View

15.

Weide B, Martens A, Hassel J, Berking C, Postow M, Bisschop K . Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res. 2016; 22(22):5487-5496. PMC: 5572569. DOI: 10.1158/1078-0432.CCR-16-0127. View

16.

Stewart T, Greeneltch K, Reid J, Liewehr D, Steinberg S, Liu K . Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells. J Cell Mol Med. 2010; 13(9B):3939-50. PMC: 3858838. DOI: 10.1111/j.1582-4934.2009.00685.x. View

17.

Gabitass R, Annels N, Stocken D, Pandha H, Middleton G . Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60(10):1419-30. PMC: 3176406. DOI: 10.1007/s00262-011-1028-0. View

18.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

19.

Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N . Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol. 1997; 7(2):246-8. DOI: 10.1007/s003300050145. View

20.

Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View